Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 10/20 | 0.57 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18974328 | 0.91 | WNT3A (0.52) | WNT3AROCK2 | |
| SCHEMBL20508214 | 0.90 | WNT3A (0.48) | WNT3APORCNROCK2 | |
| SCHEMBL20508195 | 0.90 | ROCK2 (0.47) | WNT3AROCK2 | |
| SCHEMBL20507960 | 0.89 | WNT3A (0.57) | WNT3APORCNROCK2 | |
| SCHEMBL20507968 | 0.86 | WNT3A (0.54) | WNT3APORCN | |
| SCHEMBL20507985 | 0.86 | WNT3A (0.44) | WNT3AROCK2 | |
| SCHEMBL20508030 | 0.84 | WNT3A (0.56) | WNT3APORCN | |
| SCHEMBL20508102 | 0.84 | NPC1 (0.49) | WNT3AALDH1A1ROCK2 | |
| SCHEMBL20508203 | 0.82 | MAPK1 (0.47) | WNT3APORCNROCK2 | |
| SCHEMBL20507940 | 0.82 | WNT3A (0.57) | WNT3APORCN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | claimed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | claimed |
| EP-3388428-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Company (CN) | 2018-10-17 | — | — | EP | claimed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | claimed |
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-3388428-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Company (CN) | 2018-10-17 | — | — | EP | disclosed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | WNT1, WNT3, WNT3A | WNT3A 3/4885PORCN 736/4885ALDH1A1 2969/4885 |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | WNT1, WNT3, WNT3A | WNT3A 3/4885PORCN 516/4885ALDH1A1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.